

12th International Symposium on Viral Hepatitis and Liver Disease
Paris, July 1-5, 2006

ISVHLD

PARIS 2006

12th International Symposium on Viral Hepatitis and Liver Disease

Paris, 1-5 July 2006

Palais des Congrès

SCIENTIFIC PROGRAM

www.isvhld2006.com

POSTGRADUATE COURSES

Saturday July 1

POST GRADUATE COURSE PG1

Online registration compulsory

Extending the Boundaries of Antiviral treatment for Hepatitis B and C

Saturday July 1st 2006, 8.30 am to 12.30 am

Organizers: G. Dusheiko (UK), F. Zoulim (France)

Hepatitis B therapy:

- 1) The limits of current antiviral therapy of chronic hepatitis B (G. Dusheiko, UK)
- 2) Targets for nucleoside analogs and cross resistance testing (F. Zoulim, France)
- 3) Results of clinical trials with new nucleosides analogues (A. Lok, USA)
- 4) Perspectives on combination therapy (J. Petersen, Germany)
- 5) Round table discussion

Break

Hepatitis C therapy:

- 1) How to improve efficacy and overcome non response with existing therapy (T. Baumert, France)
- 2) Improvements in the offing with new interferons and ribavirins (A. Craxi, Italy)
- 3) Specific inhibitors of HCV replication and drug resistance (J. Neyts, Belgium)
- 4) Results of clinical trials with new protease and polymerase inhibitors (M. Manns, Germany)
- 5) Round table discussion

POST GRADUATE COURSE PG2

Courtesy of an unrestricted grant by Roche but online registration requested to access

HCV Infection: The New Metabolic Frontier

Saturday July 1st 2006, 8.30 am to 13.30 am

Organizers: L. Serfaty (France), V. Ratziu (France)

Introduction and Objectives (Lawrence Serfaty, France)

Session 1: Impact of HCV infection on fat and glucose metabolism

Chairs: Arun Sanyal and Ana Mae Diehl

- ▶ Insulin resistance : clinical relevance and molecular mechanisms (Jacqueline Capeau, France)
- ▶ Does HCV alter insulin signalling? (David Brenner, USA)
- ▶ Interactions between HCV and lipid metabolism (Francesco Negro, Switzerland)
- ▶ Discussion/Questions
- ▶ Epidemiology of steatosis in chronic HCV infection (Lawrence Serfaty, France)
- ▶ HCV infection and diabetes: association by chance or by design? (Hashem El Serag, USA)
- ▶ Controversy in physiology. Insulin resistance and steatosis : which comes first?

Insulin resistance: Ana Mae Diehl (USA)

Steatosis: Giulio Marchesini (Italy)

- ▶ Discussion/Questions

Break

Session 2: Impact of insulin resistance and steatosis on the natural history of chronic hepatitis C

Chairs: Francesco Negro and Lawrence Serfaty

- ▶ How does fat trigger fibrogenesis? (Scott Friedman, USA)
- ▶ Steatosis, insulin resistance and fibrosis progression (Vlad Ratziu, France)
- ▶ Determinants and consequences of steatosis in HIV-HCV coinfection (Stanislas Pol, France)
- ▶ Controversy in pathology. Can the pathologist diagnose NASH in chronic hepatitis C?

Yes: Elisabeth Powell (Australia)

No: Pierre Bedossa (France)

- ▶ Discussion/Questions

Break

Session 3: Insulin resistance, steatosis and chronic hepatitis C : therapeutic implications

Chairs: Thierry Poynard and Vlad Ratziu

- ▶ Insulin resistance and interferon signalling (Arun Sanyal, USA)
- ▶ Impact of insulin resistance and steatosis on sustained virological response (Jenny Heathcote, Canada)
- ▶ Beyond antivirals: management of metabolic risk factors in HCV patients (Elisabeth Powell, Australia)
- ▶ Controversy in management. Should diabetic patients be screened for HCV?

Yes: Hashem El Serag (USA)

No: Amedeo Lonardo (Italy)

▶ Discussion/Questions

Closing remarks: Perspectives in hepatology and diabetology (Vlad Ratziu, France)

DETAILED SCIENTIFIC PROGRAM

Sunday July 2

7.00-8.00 am

MPB01: Future HCV Therapies - Transforming the Treatment Paradigm

sponsored by Vertex Pharmaceuticals

Chair 1: **Alberti A.**

Chair 2: **Manns M.**

8.30-10.30 am

PL1 HAV and HEV: Epidemiology, Virology, Natural History, Vaccines, Treatment

Chair 1: **Krawczinski K**

Chair 2: **Purcell R**

Speaker 1: **Martin A**

Hepatitis A: Molecular virology and pathogenesis

Speaker 2: **Bell B**

Hepatitis A: new tools for an old disease

Speaker 3: **Purcell R**

Hepatitis E: Light at the end of the tunnel ?

Speaker 4: **Krawczinski K**

Elements of pathogenesis and natural history of HEV infection

Speaker 5: **Scott R**

Protection against hepatitis E by a recombinant vaccine

11.00-12.30 am

PS01 Hepatitis delta

Chair 1: **Taylor J**

Chair 2: **Rizzetto M**

Speaker 1: **Taylor J**

Characterization of RNA-directed transcription of human hepatitis delta virus RNA

Speaker 2: **Sureau C**

The HDV/HepaRG model for in vitro analysis of the HBV envelope protein functions at viral entry

Speaker 3: **Huang C**

Cytoplasm-localized large hepatitis delta antigen interferes clathrin-mediated protein trafficking

Speaker 4: **Rapicetta M**

HDV-WHV genotypes and outcome of superinfection in woodchuck model

Speaker 5: **Parana R**

Peculiar fulminant HDV hepatitis in Amazonia

Speaker 6: **Rizzetto M**

Conclusion

PS02 Vaccines and immune response

Chair 1: **Wen Y**

Chair 2: **Torresi J**

Speaker 1: **Torresi J**

Cross-reactive epitopes identified in hepatitis C virus envelope proteins induce antibodies that capture virions from infected patients' sera and neutralize HCV/HIV pseudotypes

Speaker 2: **Inchauspé G**

Potent T-cell immunity induced by a hepatitis C virus candidate vaccine based on a non-replicative poxvirus

Speaker 3: **Michel ML**

Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects

Speaker 4: **Frey S**

A phase 1 trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002)

Speaker 5: **Folgori A**

Towards effective prophylactic and therapeutic vaccination against HCV

PS03 HBV: Animal and cellular models

Chair 1: **Roggendorf M**

Chair 2: **Jilbert A**

Speaker 1: **Michalak T**

Primary and secondary occult hepadnaviral infections: identification and differential characteristics

Speaker 2: **Roggendorf M**

Therapeutic vaccination in chronic hepatitis B: pre-clinical studies in the wood chuck

Speaker 3: **Khudyakov Y**

Expansion of HBV S gene heterogeneity in chimpanzees after experimental inoculation with HBV sT126N mutant

Speaker 4: **Petersen J**

HBV/HCV: animal/cellular models

Speaker 5: **Abou Jaoudé G**

Determinants of infectivity in the antigenic loop of hepatitis B virus envelope proteins

Speaker 6: **Glebe D**

Hepatitis B virus infection is dependent on a multistep attachment and entry process mediated by the preS1 and the S-domain

PS04 Bloodborne viruses, blood transfusion, organ transplantation

Chair 1: **Holland P**

Chair 2: **Busch M**

Speaker 1: **Holland P**
Transfusion Associated Hepatitis B Virus Infections

Speaker 2: **Busch M**
Recent insights into HCV natural history and pathogenesis from studies of infected blood donors and recipients

Speaker 3: **Chevaliez S**
Full-length preS1-preS2-HBs antigen (HBsAg) sequence analysis of HBV surface mutants in HBV DNA-positive organ, tissue and cell donors with various HBV serological profiles

Speaker 4: **Bauer T**
Vaccination against hepatitis B in liver transplant recipients with history of hepatitis B infection: analysis of cellular immune response shows evidence of HBsAg specific regulatory T cells

Speaker 5: **Dagan S**
Broad reactivity of two anti-E2 human monoclonal antibodies against HCV quasispecies after liver transplantation

PS05 HAV & HEV: Basic research, development of new vaccines

Chair 1: **Emerson S**
Chair 2: **Jameel S**

Speaker 1: **Moin S**
The HEV ORF3 protein downregulates the mitochondrial death pathway through increased expression and oligomerization of VDAC

Speaker 2: **Emerson S**
Analysis of hepatitis E virus mutants in a new cell culture system

Speaker 3: **Graff J**
Hepatitis E virus ORF2 and ORF3 proteins are encoded by a bicistronic subgenomic mRNA

Speaker 4: **Lal S**
Enhanced alpha-1 microglobulin secretion from hepatitis E virus ORF3 expressing human hepatoma cells is mediated by the tumor susceptibility gene 101

Speaker 5: **Santa-Olalla P**
Sequential saliva testing used in the investigation of a hepatitis A outbreak. Auvergne (France), December 2004

Speaker 6: **Chadha M**
Outbreaks of hepatitis A in western india: 2002-04

1.30-3.30 pm

PL2 Epidemiology of HBV, HDV and HCV

Chair 1: **Lavanchy D**
Chair 2: **Alter H**

Speaker 1: **Alter H**
Emerging infections that threaten the blood supply

Speaker 2: **Mele A**
HBV infection 25 years after the development of an effective vaccine

Speaker 3: **Alter M**
Epidemiology of acute and chronic HCV infection – implications for prevention and intervention

Speaker 4: **Deuffic-Burban S**
Prediction of HCV-related morbidity and mortality burden in France using the back-calculation method

Speaker 5: **Lavanchy D**
The importance of surveillance for the management of viral hepatitis

PS06 Molecular and clinical HBV epidemiology

Chair 1: **Magnius L**
Chair 2: **Vandamme P**

Speaker 1: **Magnius L**
Molecular tools in epidemiological investigations

Speaker 2: **Khudyakov Y**
Classification of hepatitis B virus genotypes into higher-order genetic groups

Speaker 3: **Norder H**
Molecular signature motifs of HBV subgenotypes: An analysis based on all open reading frames

Speaker 4: **Mostert M**
The added value of molecular analysis in the source and contact tracing of hepatitis B transmission in a community

Speaker 5: **Finelli L**
Incidence of acute hepatitis B in the United States, 1990-2005

Speaker 6: **Vandamme P**
Hepatitis B epidemiology and prevention: where are we in Europe in 2006?

PS07 HBV: Clinical trials

Chair 1: **Zarski JP**
Chair 2: **Hadziyannis S**

Speaker 1: **Heathcote J**
Chronic hepatitis B: When to institute treatment?

Speaker 2: **Chee-Kin H**
Treatment of hepatitis Be antigen positive disease

Speaker 3: **Hadziyannis S**
Treatment Paradigms on hepatitis Be antigen negative (HBeAg-Negative) chronic hepatitis B patients

Speaker 4: **Marcellin P**
Treatment of chronic hepatitis B with the combination of pegylated interferon with a nucleoside/nucleotide analogue

Speaker 5: **Lampertico P**
Five years of sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma

PS08 HCV: Animal and cellular models

Chair 1: **Blum H**
Chair 2: **Leroux-Roels G**

Speaker 1: **Blum H**
Introduction

Speaker 2: **Michalak TI**
Replication of infectious wild-type HCV in cultured human T cells

Speaker 3: **Woollard DJ**
Detection of intrahepatic virus-specific T-cells in marmosets with resolved GBV-B infection

Speaker 4: **Meuleman**
The Human Liver uPA-SCID Mouse: a chimeric rodent model for the study of viral Hepatitis

Speaker 5: **Vanwolleghem**
The Human Liver uPA-SCID Mouse, a preclinical model to test anti-Hepatitis C compounds

Speaker 6: **Leroux-Roëls G**
Conclusion

PS09 HBV: Immunopathogenesis and natural history

Chair 1: **Bertoletti A**

Chair 2: **Gerken G**

Speaker 1: **Bertoletti A**

Immune response and viral tolerance during chronic HBV infection

Speaker 2: **Gehring A**

Impact of human hepatocyte MHC-class I antigen presentation on virus-specific CD8 T cell function

Speaker 3: **Lim SG**

Viral quasispecies evolution in chronic hepatitis B: new light on an old story

Speaker 4: **Carey I**

The outcome of combined antiviral therapy in tolerant children with chronic hepatitis B is associated with emergence of mutations within HBV core gene immunodominant epitopes

Speaker 5: **Kumar M.**

Lamivudine treatment for acute hepatitis B - a randomized controlled trial

Speaker 6: **Gerken G**

Conclusion

PS10 HCV combination therapy

Chair 1: **Dhumeaux D**

Chair 2: **Adler M**

Speaker 1: **Murphy**

The safety and efficacy of Virmidine® plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-naïve patients infected with HCV: Phase 3 Results

Speaker 2: **Adler M**

Effectiveness and tolerability of peginteron(r) in combination with rebetol(r) in real life: the pegintrust study

Speaker 3: **Alberti A**

Antiviral treatment for HCV infection in the real practice. A nationwide Italian experience. The PROBE study

Speaker 4: **Paraná R**

Anti golgi complex antibodies during pegylated interferon therapy for hepatitis c: what does it mean?

Speaker 5: **Davila L**

Enhanced spontaneous apoptosis of peripheral blood leucocytes from HCV-infected patients is not modulated by current therapy with pegylated-interferon alpha and ribavirin

Monday July 3

7.00-8.00 am

MPB03: Prevention of Hepatocellular Carcinoma in Chronic Hepatitis Patients with Anti-viral and/or Alternative Medicines

sponsored by Minophagen Pharmaceutical Co., Ltd., Japan

Chair 1: **Omata M.**
Chair 2: **Schalm SW.**

8.30-10.30 am

PL3 HCV: Virology, Immunology, Natural History, Treatment

Chair 1: **Bartenschlager R**
Chair 2: **Miyamura T**

Speaker 1: **Bartenschlager R**
HCV: Virology, Immunology, Natural History, Treatment

Speaker 2: **Chisari F**
Robust hepatitis C virus infection in vitro: coevolution of virus and host

Speaker 3: **Rehermann B**
Innate and adaptive immune responses to HCV

Speaker 4: **Alberti A**
Natural history and treatment of HCV patients with normal ALT

Speaker 5: **McHutchison J**
Therapy of chronic hepatitis C

11.00-12.30 am

PS11 HBV: Viral resistance

Chair 1: **Lok A**
Chair 2: **Zoulim F**

Speaker 1: **Lok A**
Antiviral-resistant HBV - Can we prevent this monster from growing?

Speaker 2: **Buti M**
Treatment of HBV resistance

Speaker 3: **Villeneuve JP**
Management of HBV drug resistance in patients with severe cirrhosis and post-liver transplantation

Speaker 4: **Zoulim F**
Evaluation of replication capacity and cross-resistance of HBV drug resistant mutants

Speaker 5: **Wu H. L**
Development of RNA interference-based strategies to control hepatitis B virus clinical isolate of various genotypes and mutants and prevent emergence of resistant mutants

PS12 HCV: New therapeutic approaches

Chair 1: **Lamarre D**
Chair 2: **Foster G**

Speaker 1: **Lamarre D**

Introduction

Speaker 2: **Sherman KE**

Valopicitabine (NM283) plus peg-interferon for chronic hepatitis C in treatment naïve and nonresponder patients: interim phase IIb results

Speaker 3: **Maynard M**

Novel sustained release formulation of IFN- α -2b improves tolerability and demonstrates potent viral load reduction in a phase III HCV clinical trial

Speaker 4: **Tur-Kaspa R**

The unique inhibition mechanism of intrabodies against hepatitis C virus serine protease and their additive effect with IFN- α

Speaker 5: **Buck MM**

An adaptor protein AP-50 peptide inhibits serum-derived hepatitis C virus infection in normal human hepatocytes

Speaker 6: **Foster G**

Conclusion

PS13 HCV: Carcinogenesis

Chair 1: **Brechot C**
Chair 2: **Wands J**

Speaker 1: **Brechot C**

Introduction

Speaker 2: **Wands J**

Role of frizzled-7 receptor overexpression in HBV and HCV related human hepatocellular carcinoma

Speaker 3: **Bengochéa A**

Overexpression of the Wnt/Frizzled signal's members: a strikingly common and early event in human hepatocellular carcinoma (HCC)

Speaker 4: **Chang J**

Inhibition of hepatitis c virus replication by PKR

Speaker 5: **Shoji I**

E6-associated protein mediates ubiquitylation and degradation of hepatitis C virus core protein

PS14 HBV/HCV: Viral kinetics

Chair 1: **de Man RA**
Chair 2: **Neumann AU**

Speaker 1: **Neumann AU**

State of the art in modeling Hepatitis C viral kinetics

Speaker 2: **Pawlotsky JM**

HCV Kinetics: the target for HCV therapies

Speaker 3: **Brunetto M**

Early prediction of response to Peg-IFN α -2a or Peg-IFN α -2b plus ribavirin in the single chronic hepatitis C patients by modeling the dynamics of infected cells

Speaker 4: **Min L**

A mathematical model of dynamics for anti-HBV infection treatment with peginterferon alfa-2a

Speaker 5: **de Man RA**

Conclusion

2.00-3.30 pm

PS15 HCV: Lymphomas, extrahepatic manifestations

Chair 1: **Thomas H**

Chair 2: **Manns M**

Speaker 1: **Thomas H**

Introduction

Speaker 2: **Hermine O**

Splenic lymphoma with villous lymphocytes associated with type II cryoglobulinemia and HCV infection: a new entity?

Speaker 3: **Cacoub P**

Antiviral therapy for HCV-associated cryoglobulinemia vasculitis: a long term follow-up

Speaker 4: **Vidalino L**

Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C

Speaker 5: **Dammacco F**

HCV Infection, cryoglobulinemia and lymphomagenesis : an emerging picture

2.00-5.30 pm

PS16 HBV/HCV: Immunotherapy

Chair 1: **Michel ML**

Chair 2: **Inchauspe G**

Speaker 1: **Michel ML**

Introduction

Speaker 2: **Scott-Algara D**

Changes in NK cell repertoire after therapeutic HBV vaccination could be correlated to induction of HBV-specific T-cell responses

Speaker 3: **Wen Y**

HBsAg-HBIg complex modulates antigen presentation of dendritic cells from chronic hepatitis B patients

Speaker 4: **Yang S**

Relationship between T cell responses and suppression of viral rebound in chronic hepatitis B carriers received combination therapy with DNA vaccine and chemical drug

Speaker 5: **Schneider J**

A novel primeboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: a phase IIa clinical trial

Speaker 6: **Jilbert A**

Combination therapy with entecavir and "prime-boost" vaccines prevents the development of chronic duck hepatitis B virus infection

Speaker 7: **Lu M**

Combination therapy with antiviral drugs and immunomodulation against chronic hepatitis B virus infection: evaluation in the woodchuck model

Speaker 8: **Cova L**

Codelivery of cytokine genes with DNA vaccine to duck hepatitis B virus proteins improves its therapeutic efficacy

Speaker 9: **Davis H**

Early clinical results with CPG 10101, a new investigational antiviral TLR9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus

Speaker 10: **Worland S**

Pharmacokinetics, safety, tolerability and pharmacodynamics of the isatoribine oral prodrug ANA975 in a multidose phase 1 healthy volunteer study

Speaker 11: **Bharadwaj M**

Protective CD8+ T cell responses in hepatitis C virus infected/exposed individuals

Speaker 12: **Depla**
Development of therapeutic vaccines for hepatitis B and C

2.00-3.30 pm

PS17 HBV replication and host-cell interactions

Chair 1: **Will H**
Chair 2: **Levero M**

Speaker 1: **Will H**
Critical host factors in productive Hepatitis B virus infection

Speaker 2: **Strubin M**
The hepatitis B virus HBx protein stimulates viral replication and induces mitotic defects by binding to host cell protein DDB1

Speaker 3: **Quasdorff M**
Role of cellular differentiation for the efficiency of HBV replication

Speaker 4: **Hu J**
Viral and host factors in hepatitis B virus ccc DNA formation

Speaker 5: **Wen Y**
Replicative regulating function detected in the “turn” of the “helix clamp” of hepatitis B virus reverse transcriptase

Speaker 6: **Levero M**
Conclusion

PS18 Genetic Diversity and Diagnostic Testing in HBV and HCV Infections

Chair 1: **Gerlich W**
Chair 2: **Hollinger B**

Speaker 1: **Hollinger B**
An overview of genetic diversity and its impact on diagnostic assays

Speaker 2: **Roque-Afonso A**
HBsAg polymorphisms: implications for assay design

Speaker 3: **Avettand-Fenoel V**
Reasons for the lack of anti-HBc antibody detection in hepatitis B virus chronically infected patients

Speaker 4: **Kaczanowski R**
Genetic diversity and complexity changes correlate with early virological response during chronic Hepatitis C therapy

Speaker 5: **Ansaldi F**
Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection

Speaker 6: **Gerlich**
Variability and diagnosis of hepatitis B virus

PS19 Geographical diversity

Chair 1: **Fontanet A**
Chair 2: **Pujol F**

Speaker 1: **Pujol F**
A reappraisal of the genetic diversity of hepatitis B virus american genotypes

Speaker 2: **Araujo N**
Expression of hepatitis B virus surface antigens (HBsAg) in mammalian cells: characterization of a genotype F variant deficient in HBsAg secretion

Speaker 3: **Pineau P**
Genetic analysis of North-African hepatocellular carcinoma delineates specific alteration profiles

Speaker 4: **Galy O**
Pattern of HBV/HCV infection and TP53/beta-catenin mutations in HCC cases from thailand

Speaker 5: **Kirk G**
Risk of cirrhosis with exposure to aflatoxin and hepatitis B and C viruses

4.00-5.30 pm

PS20 HCV: Treatment failures

Chair 1: **Omata M**
Chair 2: **Poynard T**

Speaker 1: **Poynard T**
Management of treatment non responders in chronic hepatitis C

Speaker 2: **Manns M**
Results of clinical trials with new protease and polymerase inhibitors

Speaker 3: **Benhamou Y**
Phase 2B interim (week 12) results of albumin interferon alfa-2B combined with riba virin in ifn-naive, genotype 1 chronic hepatitis C infection

Speaker 4: **Trépo C**
Long-term maintenance ribavirin monotherapy in chronic hepatitis C patients not responding or intolerant to interferon alpha

Speaker 5: **Omata M**
Screening and primary to tertiary prevention of HCC

PS21 HBV: Carcinogenesis

Chair 1: **Buendia MA**
Chair 2: **Koike K**

Speaker 1: **Yen T**
Liver neoplasia induced by a cancer-associated hepatitis B virus mutant

Speaker 2: **Koike K**
Hepatitis B virus X protein causes mutation of cellular gene by ROS generation

Speaker 3: **Neuveut C**
Fonctional interaction between HBX and the histone acetyltransferase CBP/p300

Speaker 4: **Torresi J**
Mechanism of HBV-associated hepatocarcinogenesis by modulation of MAPK pathways and cell cycle regulation

Speaker 5: **Andrisani OM**
Mechanism of p53 activation by hepatitis B virus X protein leading to hepatocyte apoptosis

Speaker 6: **Melegari M**
Over-expression of oncogenic microRNA polycistron miR-17-92 in primary woodchuck hepatocellular carcinomas

PS22 Viral cellular interactions

Chair 1:
Chair 2: **Dubuisson J**

Speaker 1: **Bhat P**
HBV translocates across placental trophoblasts

Speaker 2: **Dreux M**
HDL inhibits neutralisation by HCV antibodies via a ternary interaction with the scavenger receptor BI

Speaker 3: **Benali-Furet N**

Modulation of endoplasmic reticulum (er) calcium signalling affects hepatitis C virus (HCV) protein expression and replication

Speaker 4: **Asselah T**

Two types of histologically normal liver can have different gene expression patterns: the importance of an adequate normal tissue control in gene expression studies

Speaker 5: **Buck M**

The HCV E2 protein is a kinase, with homology to auxilin 2, involved in clathrin mediated endocytosis

PS23 HCV: Epidemiology

Chair 1: **Alter M**

Chair 2: **Mele A**

Speaker 1: **Williams IT**

Hepatitis C virus transmission from healthcare workers to patients in the United States (438)

Speaker 2: **Williams IT**

Incidence and risk factors for hepatitis C in the United States, 1982–2004: the role of injection drug use

Speaker 3: **Hutchinson S**

Monitoring of end-stage liver disease associated with hepatitis C virus (HCV) infection in scotland: record-linkage study

Speaker 4: **Plancoulaine S**

Intra-familial transmission of HCV infection in a rural area from egypt

Speaker 5: **Gaudy C**

Changes in medical resource utilisation by subjects who are tested HCV seropositive during routine medical check-up (1994-2003)

Speaker 6: **Feray C**

Intrafamilial and household clustering of hepatitis C virus in rural Egypt: a phylogenetic and matrix correlation tests analysis

Tuesday July 4

8.30-10.30 am

PL4 HBV and HDV: Virology, Immunology, Natural History, Treatment

Chair 1: Vyas G
Chair 2: Chisari F

Speaker 1: Chisari F
Introduction

Speaker 2: Lai CL
The natural history of chronic hepatitis B

Speaker 3: Ferrari C
Immunopathogenesis of HBV infection

Speaker 4: Mason W
Hepatocyte turnover in the resolution of transient and progression of chronic hepaDNA virus infections

Speaker 5: Hoofnagle JH
Therapy of hepatitis B overview

Speaker 6: Farci P
Treatment of chronic hepatitis D

Speaker 7: Vyas G
Conclusion

11.00-12.30 am

PS24 HBV/HCV: Hepatocellular carcinoma

Chair 1: Bruix J
Chair 2: Colombo M

Speaker 1: Bruix J

Speaker 2: Colombo M
Surveillance of patients at risk

Speaker 3: Kew M
A phenylalanine mutation in the precore region of both hepatitis B virus and woodchuck hepatitis virus induces endoplasmic reticulum stress

Speaker 4: Merle P
High dose 3D conformal radiation therapy in cirrhotic patients with small hepatocellular carcinomas

Speaker 5: Wu JC
Correlation of HBV genotypes and mutants with long-term outcomes of patients underwent resection of hepatocellular carcinoma

Speaker 6: Beneduce L
A new class of biomarkers for hepatocellular carcinoma: igm immune complexes

PS25 HCV: Clinical trials

Chair 1: **Zeuzem S**
Chair 2: **Heathcote J**

Speaker 1: **Zeuzem S**

16 or 24 weeks of Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin (RBV) (Copegus®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: results from a large, randomised multinational study (ACCELERATE)

Speaker 2: **Ferenci P**

High SVR rates with 24 weeks of Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin (Copegus®) in HCV genotype 1 or 4 patients with a week-4 virological response

Speaker 3: **Esteban R**

A study to assess treatment with Peginterferon alfa2b and Ribavirin in naïve patients with genotype 1 chronic hepatitis C and slow virological response (Success Study)

Speaker 4: **Wright T**

Rapid and Early Viral Responses: Modifying treatment, not outcomes

Speaker 5: **Maylin S**

Eradication of HCV and regression of fibrosis, in chronic hepatitis C patients with sustained virological response to therapy

PS26 HBV: Mutants

Chair 1: **Tong S**
Chair 2: **Carman W**

Speaker 1: **Tong S**

Naturally occurring mutations that regulate hepatitis B e antigen expression

Speaker 2: **Harrisson T**

Basal core promoter mutations and primary liver cancer

Speaker 3: **Margeridon S**

Rolling circle amplification technology for the study fo HBV variants

Speaker 4: **Karayiannis P**

Replication efficiency of hepatitis B virus infectious clones bearing core promoter, pre-core and surface gene mutations, in a common genetic background

Speaker 5: **Pollicino T**

Characterization and functional analyses of hepatitis B virus (HBV) isolated from liver tissue of patients with occult HBV infection

Speaker 6: **Carman W**

Conclusion

PS27 HCV particles and replication cycle

Chair 1: **Liang J**
Chair 2: **Cosset FL**

Speaker 1: **Cosset FL**

HDL inhibits HCV neutralisation by CD81-NOB antibodies by stimulating cell entry through activation of the scavenger receptor B1

Speaker 2: **Liang J**

Production of infectious hepatitis C of various genotypes in cell culture

Speaker 3: **Baumert T**

Virus-Host Interactions During the First Steps of Viral Infection: Host Cell Responses Induced by Cellular Binding of Hepatitis C Virus-like Particles

Speaker 4: **Dubuisson J**

Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus

Speaker 5: **Petit MA**

Cell culture-, Serum- and Liver-Derived Hepatitis C Virus Particles: Biophysical properties, infectivity and neutralization

2.00-3.30 pm

PS28 HBV/HCV: Chronic liver failure and transplantation

Chair 1: **Samuel D**

Chair 2: **Terrault N**

Speaker 1: **Mutimer D**

Treatment of HBV cirrhotic patients before transplantation

Speaker 2: **Terrault N**

Prophylaxis and treatment of HBV reinfection

Speaker 3: **Samuel D**

Prognosis factors of HCV reinfection after liver transplantation

Speaker 4: **Forns X**

Prevention and treatment of HCV reinfection

Speaker 5: **Rifai K**

Longer survival of liver transplant recipients with hepatitis virus coinfections

PS29 HBV - New antivirals

Chair 1: **Pawlostky JM**

Chair 2: **Craxi A**

Speaker 1: **Pawlostky JM**

Speaker 2: **Craxi A**

Speaker 3: **Yurdaydin C**

Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

Speaker 4: **Urban S**

In vivo inhibition of hbv infection by acylated preS peptides in the urokinase-type plasminogen activator (UPA) mouse model

Speaker 5: **Hernandez-Santiago BI**

Drug-drug interaction between clevidine in combination with telbivudine or 3TC in human liver cells

PS30 HCV: Immunopathogenesis: cellular, humoral and innate response

Chair 1: **Diepolder H**

Chair 2: **Baumert T**

Speaker 1: **Diepolder H**

Introduction

Speaker 2: **Lauer G**

Differential responsiveness of CD4 and CD8 T-cells during acute HCV re-infection

Speaker 3: **Schlaak JF**

The primary transcriptional response to interferon-alpha2a and -alpha2b in patients with chronic hepatitis C correlates with the immediate and sustained antiviral response

Speaker 4: **Mihm S**

Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection

Speaker 5: **Dharel N**

Inhibition of hepatitis C virus replication by tumor suppressor p53: novel prospects of p53 in antiviral defense

PS31 HCV replication and host-cell interactions

Chair 1: **Wakita T**

Chair 2: **Seeger C**

Speaker 1: **Wakita T**

Production of Infectious Hepatitis C Virus in Cultured Cells

Speaker 2: **Zeisel M**

Scavenger receptor class B type 1 is a co-receptor for infection with cell culture-derived hepatitis C virus

Speaker 3: **Féray C**

Internal ribosomal entry site (IRES)-dependent tropism of hepatitis C virus

Speaker 4: **Penin F**

Interaction of HCV proteins with host cells membranes and lipids

Speaker 5: **Miyamura T**

Production of infectious HCV particles in three-dimensional liver cultures

Speaker 6: **Seeger C**

Interferon response against HCV

PS32 Late Breakers

4.00-6.00 pm

PL05 Late-brakers/Controversies and Perspectives

Chair 1: **Wright T**

Chair 1: **Mason W**

Chair 2: **Dienstag J**

Chair 3: **Bonino F**

Speaker: **Tillman H**

Shall we treat acute hepatitis B virus infection?

Speaker: **Neumann AU**

Treatment of chronic HBV - optimization of the mean results by individualized viral kinetics analysis

Speaker: **Protzer**

Immune Clearance of Hepatitis B Virus: New insights

Speaker: **Houghton M**

Perspective on Hepatitis C for the Future

Speaker: **Garnier P**

Severe acute hepatitis during Chikungunya virus infection on Reunion Island: case report from 14 observations

Wednesday July 5

8.00-10.00 am

PL06 Hepatitis A and B vaccination and public health

Chair 1: Hollinger B
Chair 2: Van Damme P

Hepatitis B vaccination programmes in the world: current operational status
(Steven Wiersma, WHO, Geneva, Switzerland)

Impact and effectiveness of universal hepatitis B vaccination programmes: country examples
(Hal Margolis, IVI, Seoul, S-Korea)

Epidemiology of hepatitis B and current vaccination programme in France
(Daniel Levy-Bruhl, InVS, Paris, France)

Discussion

Is there a role for more immunogenic hepatitis B vaccine(s)?
(Daniel Shouval, Hadassah University Hospital, Israel)

Universal hepatitis A vaccination programmes
(Beth Bell, CDC, Atlanta, USA)

Discussion and closing

SATELLITE SYMPOSIA

SS01: Satellite Symposium sponsored by Schering-Plough

Clinical Pathways Toward an Ideal HCV Therapy

Saturday July 1, 2006 from 2:00 pm to 3:30 pm

Chairmen: A. Craxi, C. Trepo

14:00-14:05

Welcome and Statement of Goals (C. Trepo)

14:05-14:20

Motivating Genotype 1 Patients towards Treatment (R. Esteban)

14:20-14:40

Predicting Response in Genotype 2 and 3 Patients (A. Alberti)

14:40-14:55

Evolving Therapeutic Pathways in Hepatitis C (J. McHutchison)

14:55-15:05

HCV Protease Inhibitors and the Future of HCV Therapy (S. Zeuzem)

14:05-15:30

Panel Discussion and Concluding Remarks (A. Craxi)

SS02: Satellite Symposium sponsored by Bristol-Myers Squibb

From Hope to Action: Emerging Strategies in the Management of CHB

Saturday July 1, 2006 from 4:00 pm to 5:30 pm

4:00 pm

Chairman's welcome (Assoc. Professor Morris Sherman, Toronto, Canada)

4:10 pm

Markers of success (Professor Graham Foster, London, UK)

4:30 pm

Who to treat (Dr Marc Bourlière, Marseille, France)

4:50 pm

Why choice of first-line treatment matters (Professor Antonio Craxi, Palermo, Italy)

5:10 pm

Panel discussion

5:25 pm

Concluding comments

5:30 pm

Close

SS03: Satellite symposium sponsored by Gilead

New HBV Data: What do we do now? - Practical Insights

Sunday July 2, 2006 from 6.00 pm to 7.30 pm

6:00-6:05

Welcome and statement of goals (JM. Pawlotsky)

6:05-6:25

Viral resistance with antiviral therapy for HBV: What does it mean today? (F. Zoulim)

6:25-6:45

Managing HBV in 2006: What is the optimal treatment strategy? (P. Lampertico)

6:45-7:05

Evolving clinical strategies in HBV: New treatment paradigms (R. Esteban)

7:05-7:30

Panel discussion

SS04: Satellite symposium sponsored by Vertex Pharmaceuticals

Transforming HCV Treatment: The Potential of Specifically Targeted Antiviral Therapy for HCV (STAT-C)

Sunday July 2, 6.00 - 7.30 pm

6:00 - 6:05

Introduction (Alfredo Alberti, MD)

6:05 - 6:25

Modeling, Kinetics, and Resistance Profiles of New Protease and Polymerase Inhibitors (Stefan Zeuzem, MD)

6:25 - 6:45

Update on Current Clinical Trial Results (Yves Benhamou, MD)

6:45 - 7:05

Clinical Implications of Treatment Paradigm Shifts in HCV (John G. McHutchison, MD, FRACP)

7:05 - 7:25

Q & A

Panel Discussion

7:25 - 7:30

Summary, Conclusions, and Close (Alfredo Alberti, MD)

SS05: Satellite Symposium sponsored by **Idenix / Novartis**

Monday July 3, 2006 from 6.00 pm to 7.30 pm

Co-chairs: Michael Houghton (USA)
Michael Manns (Germany)

6.00-6.05

Welcome and introduction

6.05-6.15

The path behind us - what can we achieve with the current standard of care? (Graham Foster, UK)

6.15-6.35

New paths to treating HCV - exploring novel modes of action (Stefan Zeuzem, Germany)

6.35-6.55

Paths of least resistance - a key challenge for new HCV antivirals (Fabien Zoulim, France)

6.55-7.10

On parallel paths - learning from HIV for success in HCV (Jürgen Rockstroh, Germany)

7.10-7.20

Curing HCV in the future - the path ahead (Michael Manns, Germany)

7.20-7.30

Q&A and close (Faculty)

SS06: Satellite Symposium sponsored by **Chiron**

Occult hepatitis B - Diagnosis and Pathogenesis

Monday July 3, 6.00 - 7.30pm

6.00-6.05

Welcome and opening (Nico Lelie, Chiron, France)

6.05-6.30

HBV screening in liver donors (Jean-Michel Pawlotsky, Hopital Henri Mondor, Creteil, France)

6.30-6.55

Occult HBV infection and pathogenesis (Giovanni Raimondo, University of Messina, Italy)

6.55-7.20

Infectivity of HBsAg negative blood donations: early phase and escape mutants (Wolfram Gerlich, University of Giessen, Germany)

7.20-7.30

Discussion

Moderators Solko Schalm, Erasmus University Hospital, Rotterdam

Nico Lelie, Chiron, France

7.30

Closure

For registration, please contact the Congress Office:

ISVHLD 2006 c/o MCI

24, rue Chauchat – 75009 Paris – France

Tel.: +33 (0)1 53 85 82 68 – Fax.: +33 (0)1 53 85 82 83

e.mail: isvhld2006@mci-group.com

Or register on line: www.isvhld2006.com